ArticleHereditas2026
Efficacy of nano-silver small intestine submucosa repair of osteochondral defect in rabbit model by the AMPK-mTOR-ULK1 pathway.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveThis study evaluated the regenerative potential of nano-silver small intestine submucosa (NSSIS) scaffolds with a 4-D porous structure for repairing osteochondral defects in rabbit knee joints.
methodsNSSIS scaffolds were prepared using nanosilver, fresh pig-derived small intestinal submucosa, and chondrocytes. Biocompatibility was assessed by methyl thiazolyl tetrazolium (MTT) assays measuring bone marrow stromal cell (BMSC) proliferation at 24, 48, and 72 h. A rabbit model of intercondylar groove cartilage defects was established and randomized into three groups (n = 12 each): NSSIS, NSSIS + BMSCs, and a control group. Scaffold morphology and cell growth were evaluated in vitro using H&E staining after 24 h. Following implantation, cartilage repair was assessed at 24, 48, and 72 h using ICRS macroscopic scoring and histological staining (H&E, Safranin O-fast green, toluidine blue). After 12 weeks, ELISA measured growth factor expression (PDGF, VEGF, TGF-β, IGF-1, FGF, EGF), and qRT-PCR and Western blotting assessed autophagy-related gene and protein expression (AMPK, ULK1, mTOR, and Beclin-1).
resultsBoth NSSIS groups demonstrated significantly greater BMSC ingrowth compared with controls, with the NSSIS + BMSCs group exhibiting the most robust repair. This group showed significantly elevated growth factor expression at 12 weeks (p < 0.05), downregulation of AMPK, ULK1, and Beclin-1, and upregulation of mTOR (p < 0.01). Histological analysis revealed enhanced chondrocyte formation, thicker cartilage layers, increased chondroblast proliferation, and abundant extracellular matrix deposition in the NSSIS + BMSCs group, whereas the NSSIS-only group showed less cellular and collagen development.
conclusionsNSSIS scaffolds demonstrate good biocompatibility and promote BMSC ingrowth, chondrocyte development, and osteochondral repair. The addition of BMSCs further enhances these effects by facilitating in situ chondrogenic differentiation, stimulating BMSC and chondrocyte migration, and initiating tissue regeneration. These findings highlight the potential of NSSIS, particularly when combined with BMSCs, as a promising biomaterial for cartilage and subchondral bone repair, with potential clinical applications in regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.